INPEFA Receives Preferred Formulary Status With Express Scripts For Medicare Patients, Inpefa Recently Approved By FDA For Treatment Of Heart Failure
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals' heart failure treatment, INPEFA, has been approved by the FDA and will be listed as a preferred product on Express Scripts' Medicare national formularies from November 1, 2023. This will provide access to INPEFA for Express Scripts Medicare patients who meet the parameters of INPEFA's FDA-approved indication.
October 09, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals' stock may see a positive impact as its product, INPEFA, has received FDA approval and will be listed as a preferred product on Express Scripts' Medicare national formularies.
The FDA approval of INPEFA and its inclusion in Express Scripts' Medicare national formularies is a significant milestone for Lexicon Pharmaceuticals. This could lead to increased sales of INPEFA, which would positively impact the company's revenues and potentially its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100